• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Maxcyte Inc (NQ: MXCT )

    4.050 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 4.050
    Bid (Size) 1.630 (1)
    Ask (Size) 6.480 (2)
    Prev. Close 4.050
    Today's Range 4.050 - 4.050
    52wk Range 2.450 - 5.545
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
    Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T... 
    From MaxCyte, Inc
    Via GlobeNewswire

    Performance

    YTD
    -19.00%
    -19.00%
    1 Month
    -18.35%
    -18.35%
    3 Month
    -2.17%
    -2.17%
    6 Month
    -11.76%
    -11.76%
    1 Year
    -18.84%
    -18.84%

    More News

    Read More
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    MaxCyte Earnings Preview
    Via Benzinga
    Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
    From MaxCyte, Inc
    Via GlobeNewswire
    Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
    From MaxCyte, Inc
    Via GlobeNewswire
    Earnings Scheduled For March 12, 2024
    Via Benzinga
    MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
    From MaxCyte, Inc
    Via GlobeNewswire
    Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Cell Engineering Company MaxCyte Shares Are Up Today
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
    From MaxCyte, Inc
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.